Qaytona is free while it's in beta — Get started

Sign in
Ingredients

Bibhitaki

Terminalia bellirica · Bahera · Beleric Myrobalan

Snapshot

IndicationsContraindications
  • Oral antimicrobial support1
  • LDL oxidation inhibition2
  • Macrophage inflammatory response2

    Human research is limited to one small crossover trial covering oral antimicrobial activity and one in-vitro study on lipid oxidation and macrophage inflammation. A 2016 in-vitro study found that Terminalia bellirica extract inhibited low-density lipoprotein (LDL) oxidation and suppressed pro-inflammatory gene expression in macrophages, with no human trial yet replicating these effects2. A crossover trial found that a rinse containing T. bellirica reduced salivary Streptococcus mutans colony-forming units, though Triphala as a combination outperformed the individual constituent1. With 756 products listing Bibhitaki on the market, it is available primarily in liquid, powder, and capsule forms, most often as part of Triphala blends; see Form comparison.

    No authoritative guideline contraindication is documented for this ingredient; the absence of safety data in pregnancy and pediatric populations represents an unstudied gap rather than a confirmed harm.

    Last updated October 9, 2026. Read how we make monographs.

    In the full monograph

    20 sources, 10 studies

    • When to useThe situations practitioners use it for, each with the reason and the study behind it.
    • SafetyWho should avoid it, who needs extra care, and the side effects reported in studies.
    • InteractionsThe medicines and supplements it interacts with, the effect of each, and what labeling says to watch.
    • Protocol notesThe doses used in studies, how and when they were taken, and how the forms on the market compare.
    • How it worksWhat it is and how it works in the body, in plain terms.
    • Published studiesThe studies behind each use, popular claims checked against them, and trials still under way.
    • Word of mouthWhat patients and practitioners report online, kept separate from the clinical evidence.
    • Clinical perspectiveA closing read of where the evidence is solid, where it is thin, and what has not been studied.
    Sign in to read the full monograph

    Sources

    1. 1Anti Bacterial Efficacy of Terminalia Chebula, Terminalia Bellirica, Embilica Officinalis and Triphala on Salivary Streptococcus Mutans Count - A Linear Randomized Cross Over Trial.pubmed.ncbi.nlm.nih.govSaxena, Lakshminarayan, Gudli et al. · Journal of clinical and diagnostic research : JCDR · 2017 · Pubmed
    2. 2Terminalia bellirica Extract Inhibits Low-Density Lipoprotein Oxidation and Macrophage Inflammatory Response in Vitro.pubmed.ncbi.nlm.nih.govTanaka, Kishimoto, Saita et al. · Antioxidants (Basel, Switzerland) · 2016 · Pubmed